Understanding how Merkel cell skin cancer develops
Official title: Unraveling the regulatory circuits that drive Merkel cell carcinoma
Funded at University of Arizona · NIH-11136473 · Data updated 2026-11-12
This research explores how a specific virus causes Merkel cell carcinoma, a rare and aggressive skin cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | August 10, 2021 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $341,513 |
| NIH project number | 5R01CA251729-05 |
| Project ID | NIH-11136473 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is relevant for patients diagnosed with Merkel cell carcinoma, particularly those whose cancer is linked to the Merkel cell polyomavirus.
✕Less likely to help
Patients with cancers unrelated to Merkel cell carcinoma or its viral cause may not directly benefit from this specific research.
What this research studies
Merkel cell carcinoma is a serious skin cancer that can be caused by the Merkel cell polyomavirus. We are looking at how two specific viral genes, called ST and LT antigens, change normal cells to become cancerous and spread. By studying these changes in a controlled setting, we can observe the exact steps that lead to tumor formation. This approach helps us understand the disease's progression in a way that is not possible by just looking at existing tumors.
Why it matters
Potential benefit: If successful, this work could lead to new ways to prevent or treat Merkel cell carcinoma by targeting the specific mechanisms that drive its development.
How similar studies have gone: While the viral etiology of Merkel cell carcinoma offers a unique opportunity, this specific approach to systematically quantify regulatory changes during carcinogenesis is novel.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Padi, Megha — University of Arizona
- Study coordinator: Padi, Megha
Related research
Other NIH-funded projects on the same topics.
-
Immunobiology and Immunotherapy for Merkel Cell Carcinoma
A team at the University of Washington is advancing how the immune system fights a rare skin cancer called Merkel cell carcinoma and testing new immune-based treatments to help patients who don’t respond to existing therapies.
-
New therapies for Merkel cell carcinoma and its immune environment
A cancer grant is testing a drug that may boost immune therapies and help patients with Merkel cell carcinoma who don’t respond to current treatments.
-
New treatments for Merkel cell carcinoma
This research looks for new ways to treat Merkel cell carcinoma, a serious skin cancer, especially for patients who don't respond to current therapies.
-
Immune therapies for Merkel cell carcinoma
This project develops and tests new immune-based treatments to help people with Merkel cell carcinoma, especially those whose cancers no longer respond to PD‑1 drugs.
-
Investigating a new treatment for Merkel cell carcinoma
This study is looking at a type of skin cancer called Merkel cell carcinoma, especially in older Veterans, to see how a specific protein affects the cancer and to test a new treatment that could help those who can't use current therapies.
-
Understanding why some patients with Merkel cell carcinoma resist immunotherapy
This study is looking into why some people with Merkel cell carcinoma, a tough type of skin cancer, don’t respond well to immunotherapy, and it hopes to find clues that could help improve treatment for those patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.